Verdezyne Received $1.7M Grant from National Institute of Allergy And Infectious Diseases

Verdezyne, Inc., a synthetic biology company developing fermentation processes for industrial chemicals and biofuels, received a $1.7m grant from the National Institute of Allergy And Infectious Diseases (NIAID) for a period of 18 months.
The grant aims to advance the construction of directed mutant gene libraries widely considered important technology tools for synthetic biology.
The Carlsbad, CA-based company will apply their proprietary computational and bioinformatics programs to create highly diverse gene libraries to further enhance metabolic engineering tools. This enhanced capability will be directly useful to life science researchers, and serve as a platform for protein and metabolic engineering.
As stated by Stephen Picataggio, Ph.D., Chief Scientific Officer of Verdezyne, “This grant will fund research to progress the role of bioinformatics in synthetic biology.
“By advancing this technology, we will be able to utilize the computational tools for improved protein expression and function for our internal biofuel and biobased chemical programs”.

Join the discussion